Archive: 2017

 

 

Avita Medical and BARDA Execute a US$24.3m Contract Option

Valencia, CA, USA, Perth, Australia and London, United Kingdom, 21 September 2017 — Avita Medical (ASX: AVH), (OTCQX: AVMXY),  - link here a regenerative medicine company specializing in the treatment...

Read more about Avita Medical and BARDA Execute a US$24.3m Contract Option

Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler

12 Sep 2017 - link here

Read more about Adherium Releases Next Generation Adherence Monitor, SmartTurbo Model 4, for AstraZeneca’s Turbuhaler

AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

A patient suffering from a life-threatening staphylococcal endocarditis received AB-SA01 under expanded access regulatory guidelines

Read more about AmpliPhi Biosciences Announces First Intravenous Treatment of a Patient with AB-SA01 Targeting Staphylococcus aureus

AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on the development of therapies for antibiotic-resistant infections using bacteriophage technology, announces that it has received a...

Read more about AmpliPhi Biosciences Announces Receipt of $2.0 Million R&D Tax Incentive

Adherium Receives FDA Clearance for Smartinhaler sensor for AstraZeneca's Symbicort inhaler

04 Sep 2017 - link here

Read more about Adherium Receives FDA Clearance for Smartinhaler sensor for AstraZeneca's Symbicort inhaler

BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments

BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments

Read more about BioScience Managers Appoints Elizabeth Klein as Investment Consultant in the UK to Support Bioscience Managers’ and Downing’s Life Sciences Investments

Adherium Appoints New CEO to Drive Global Growth

9 June 2017:link here

Read more about Adherium Appoints New CEO to Drive Global Growth

Dr Michael S. Perry appointed Avita Medical CEO

US-based CEO aligns with Avita’s increasing US orientation with BARDA contract, completed Phase 3 trial, imminent PMA submission, and pending US approval & commercialization • Mike Perry former Novartis Executive...

Read more about Dr Michael S. Perry appointed Avita Medical CEO

AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

SAN DIEGO--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development of therapies to treat drug-resistant infections using bacteriophage-based technology, announces the appointment of Paul C. Grint, M.D.

Read more about AmpliPhi Biosciences Appoints Paul C. Grint, M.D. as Chief Executive Officer

Avita Medical’s Board show confidence in company by taking payment in shares

Directors take up to 100 per cent of fees in shares • Follows shareholder approval of employee share plan in November last year Northridge, CA, USA, Perth, Australia and Cambridge,...

Read more about Avita Medical’s Board show confidence in company by taking payment in shares

1 2 3 4 5